New Eliquis Lawsuit Alleges Drug Caused Partial Blindness

Public Health Watchdog Breaking News
Public Health Watchdog Breaking News

Pharmaceutical giants Pfizer Inc. and Bristol-Myers Squibb are facing a new Eliquis bleeding lawsuit from a Louisiana man who alleges the drug caused serious internal bleeding injuries.

In legal documents, the man alleges the drug makers failed to warn him about potential complications, including the long-term health conditions he now suffers from.

The plaintiff began taking Eliquis (apixaban) in June 2013 to treat atrial fibrillation, a heart rhythm abnormality. He discussed treatment options with his doctor before starting Eliquis. He says at no point during the prescription period were he or his physician aware of internal bleeding complications, nor did the company make any such disclosures. The man took Eliquis until April 2016, and he says he used the medication as directed. But he says that despite his diligence in following prescription instructions, he suffered severe internal eye bleeding on August 25, 2015. The eye problems continued for several months. The bleeding complications were treated, but the plaintiff is now partially blind in his right eye.

The plaintiff has filed this Eliquis bleeding lawsuit because he now endures chronic pain and suffering as a result of using the anticoagulant.

Eliquis is one of a new generation of anticoagulants, introduced as better alternatives to warfarin, which has been the standard anticoagulant treatment for six decades. The new drugs do not require regular blood tests and dietary restrictions, as warfarin does. Advertising for the new drugs emphasizes the convenience of these new blood thinners compared to warfarin.

The U.S. Food and Drug Administration (FDA) approved Eliquis in 2012. The drug was released as a joint effort between Pfizer and Bristol Myers. Eliquis quickly became a market success, but patients soon began reporting bleeding problems. Blood thinners work by inhibiting the body’s clotting mechanism, which improves the body’s blood circulation. But the inhibited clotting ability makes it difficult for the individual to recover from internal bleeding and this puts patients at risk for potentially fatal complications. Eliquis does not have a reversal agent to restore clotting ability. Warfarin does have an antidote.

The plaintiffs allege that Pfizer and Bristol-Myers Squibb failed to mention the bleeding risks on the Eliquis warning label. In his Eliquis bleeding lawsuit, the man suffering partial blindness says the companies either knew or should have known of these complications. Further, the man says he never would have taken Eliquis if he had known the risks of internal bleeding. He is seeking damages for multiple counts of negligence and failure to warn.